Characteristics | Training cohort (n = 4495) | Validation cohort (n = 1924) | p value |
---|---|---|---|
Age (year) | n (%) | n (%) | 0.070 |
  < 40 | 38 (0.8%) | 6 (0.3%) |  |
 40–60 | 1010 (22.5%) | 454 (23.6%) |  |
 60–80 | 2984 (66.4%) | 1280 (66.5%) |  |
  ≥ 80 | 463 (10.3%) | 184 (9.6%) |  |
Gender | Â | Â | 0.102 |
 Female | 2226 (49.5%) | 910 (47.3%) |  |
 Male | 2269 (50.5%) | 1014 (52.7%) |  |
Race | Â | Â | 0.413 |
 White | 3712 (82.6%) | 1596 (83.0%) |  |
 Black | 411 (9.1%) | 186 (9.6%) |  |
 Others | 372 (8.3%) | 142 (7.4%) |  |
8th T stage | Â | Â | 0.100 |
 T1 | 739 (16.4%) | 293 (15.2%) |  |
 T2 | 2798 (62.2%) | 1195 (62.1%) |  |
 T3 | 786 (17.5%) | 376 (19.6%) |  |
 T4 | 172 (3.8%) | 60 (3.1%) |  |
8th N stage | Â | Â | 0.931 |
 N0 | 1321 (29.4%) | 561 (29.1%) |  |
 N1 | 1823 (40.6%) | 790 (41.1%) |  |
 N2 | 1351 (30.0%) | 573 (29.8%) |  |
Grade | Â | Â | 0.086 |
 Well | 476 (10.6%) | 222 (11.5%) |  |
 Moderate | 2355 (52.4%) | 1005 (52.2%) |  |
 Poor | 1638 (36.4%) | 676 (35.2%) |  |
 Undifferentiated | 26 (0.6%) | 21 (1.1%) |  |
LNR | Â | Â | 0.590 |
 1 | 3086 (68.7%) | 1334 (69.3%) |  |
 2 | 1409 (31,3%) | 590 (30.7%) |  |
Tumor size (cm) | Â | Â | 0.909 |
  ≤ 2.5 | 1547 (34.4%) | 665 (34.6%) |  |
  > 2.5 | 2948 (65.6%) | 1259 (65.4%) |  |
Radiotherapy | Â | Â | 0.647 |
 No/unkown | 3054 (67.9%) | 1296 (67.4%) |  |
 Yes | 1441 (32.1%) | 628 (32.6%) |  |
Chemotherapy | Â | Â | 0.999 |
 No/unkown | 1133 (25.2%) | 485 (25.2%) |  |
 Yes | 3362 (74.8%) | 1439 (74.8%) |  |
8th AJCC stage | Â | Â | 0.749 |
 Stage I | 1100 (24.5%) | 460 (23.9%) |  |
 Stage II | 1931 (43.0%) | 846 (44.0%) |  |
 Stage III | 1464 (32.5%) | 618 (32.1%) |  |
RLNs | 17 [12–24] | 17 [11.25–23] | 0.409 |
PLNs | 2 [0–4] | 2 [0–4] | 0.689 |
mOS (months) | 16 [8–28] | 16 [9–27] | 0.539 |